Search - tctmd.com

Displaying 1 - 16 of 16

Sort: Relevancy | Date

News Opinion CV Team Dispatch

April 2025 Dispatch for the CV Team

L.A. McKeown

April 18, 2025

News Daily News

FINEARTS-HF: Topline Results Support Role for Finerenone in Mildly Reduced or Preserved EF

L.A. McKeown

August 05, 2024

News Daily News

Daily Texts Boost Self-care in HFrEF but Don’t Impact Outcomes

L.A. McKeown

December 08, 2023

News Conference News HFSA 2023

STRONG-HF Analysis: Safety Events Common but Manageable in GDMT Optimization

L.A. McKeown

October 18, 2023

News Daily News

Meth-Related HF: Challenges at the Intersection of CVD and Addiction

Caitlin E. Cox

December 06, 2022

News Daily News

Sodium Restriction No Help, No Harm in HF, Meta-analysis Confirms

Shelley Wood

November 23, 2022

News Conference News ESC Heart Failure 2022

Dapagliflozin Boosts Health Status Across LVEF Range

Shelley Wood

May 23, 2022

News Daily News HFSA 2021

In HF and Diabetes, Mobile Health App Modestly Boosts Physical Activity

Michael O'Riordan

September 15, 2021

News Conference News HFSA 2020

Splanchnic Nerve Ablation Improves HFpEF Symptoms, QoL in FIH Study

L.A. McKeown

October 12, 2020

News Conference News HFSA 2020

EMBRACE HF: Empagliflozin Cuts PA Pressure in HF With or Without Diabetes

L.A. McKeown

October 09, 2020

News Conference News CRT 2020

Small Study Hints Rivaroxaban Helps Cut Stroke in A-fib Patients Post-TAVR

L.A. McKeown

February 24, 2020

News Conference News ESC 2019

ESC 2019: Antiplatelets in Diabetes, CAD and A-fib, an ARNI in HFpEF, Staged Complete PCI, and More

Shelley Wood

August 22, 2019

News Daily News

Mobile Health Technologies May Boost Diagnosis, Care for Patients With Structural Heart Disease

Yael L. Maxwell

September 15, 2017

News Daily News

利拉鲁肽超越 FDA 安全预期，可降低心血管疾病的死亡率：LEADER

Michael O'Riordan

June 14, 2016

News Daily News

Liraglutide Leaps Over FDA Safety Hurdle, With Cardiovascular Mortality Reduction to Boot: LEADER

Michael O'Riordan

June 14, 2016

News Daily News

Estudio LEADER: Liraglutide se Salta la Valla de Seguridad de la FDA al Confirmarse un Descenso de la Mortalidad Cardiovascular

Michael O'Riordan

June 14, 2016

Advertisement

April 2025 Dispatch for the CV Team

FINEARTS-HF: Topline Results Support Role for Finerenone in Mildly Reduced or Preserved EF

Daily Texts Boost Self-care in HFrEF but Don’t Impact Outcomes

STRONG-HF Analysis: Safety Events Common but Manageable in GDMT Optimization

Meth-Related HF: Challenges at the Intersection of CVD and Addiction

Sodium Restriction No Help, No Harm in HF, Meta-analysis Confirms

Dapagliflozin Boosts Health Status Across LVEF Range

In HF and Diabetes, Mobile Health App Modestly Boosts Physical Activity

Splanchnic Nerve Ablation Improves HFpEF Symptoms, QoL in FIH Study

EMBRACE HF: Empagliflozin Cuts PA Pressure in HF With or Without Diabetes

Small Study Hints Rivaroxaban Helps Cut Stroke in A-fib Patients Post-TAVR

ESC 2019: Antiplatelets in Diabetes, CAD and A-fib, an ARNI in HFpEF, Staged Complete PCI, and More

Mobile Health Technologies May Boost Diagnosis, Care for Patients With Structural Heart Disease

利拉鲁肽超越 FDA 安全预期，可降低心血管疾病的死亡率：LEADER

Liraglutide Leaps Over FDA Safety Hurdle, With Cardiovascular Mortality Reduction to Boot: LEADER

Estudio LEADER: Liraglutide se Salta la Valla de Seguridad de la FDA al Confirmarse un Descenso de la Mortalidad Cardiovascular

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content